In fact, the addition of uremic serum from HD patients enhances eryptotic markers on red blood cells (RBCs) from healthy controls, while inhibition of the organic anion transporter 2 with ketoprofen (that inhibits the uptake of uremic toxins by RBCs) and the incubation of HD patients’ RBCs with serum from healthy controls reverted eryptosis, suggesting a direct role of uremic toxins in RBC eryptosis in CKD [30]. The gene discussed is SLC22A7; the disease is Huntington disease.